ViCentra has appointed Reman McDonagh, PhD, as Vice President, Global Marketing, to provide senior commercialization leadership as the company scales execution across Europe and advances preparations for its next-generation Kaleido insulin patch pump system, including planned launches in the EU and the U.S.
McDonagh brings more than two decades of global experience in diabetes and medical device commercialization, spanning early-stage innovation through large-scale international growth. Her background includes leadership roles at Roche, Medtronic, Cellnovo, and Insulet, where she led brand strategy, go-to-market planning, market development, and major product launches across established and high-growth markets. Most recently at Insulet, she led the direct European launch of Omnipod DASH across 12 countries and helped shape the regional launch strategy for Omnipod 5.
The appointment follows ViCentra’s recent $98 million Series D financing extension and is part of a broader buildout of the company’s commercial leadership as it moves from early traction to more disciplined, repeatable scaling. In her new role, McDonagh will be responsible for the global marketing strategy, with an emphasis on sharpening Kaleido’s value proposition, accelerating demand generation in priority European markets, and coordinating cross-functional readiness for upcoming product launches.
ViCentra is headquartered in Utrecht and is expanding across Europe while preparing for entry into the U.S. market. The company highlights a design-led approach to insulin delivery through Kaleido and notes system integration with Diabeloop hybrid closed loop algorithms DBLG1 and DBLG2. ViCentra’s investor base includes Innovation Industries, Partners in Equity, Invest-NL, EQT Life Sciences, ROM Utrecht Region, Venturing Tech, Health Innovations, and INKEF.
KEY QUOTES
“Reman joins ViCentra at a pivotal stage as we transition from strong early traction to disciplined, scalable growth. She brings a rare combination of deep diabetes expertise, end-to-end marketing leadership, and operational rigor, as we strengthen our presence in key European markets and prepare for U.S. market entry.”
Tom Arnold, Chief Executive Officer, ViCentra
“Kaleido is a truly differentiated insulin delivery system, and ViCentra has built meaningful momentum through a clear focus on the user experience. I’m excited to join the team as we scale in key markets and prepare for the next generation of Kaleido, bringing greater choice, flexibility, and freedom to more people living with diabetes.”
Reman McDonagh, Vice President, Global Marketing, ViCentra
